Real-life incidence of cardiotoxicity and associated risk factors in sarcoma patients receiving doxorubicin

Authors

  • Joanna Vitfell-Rasmussen Department of Oncology, Sarcoma Unit, Herlev University Hospital, Herlev, Denmark
  • Anders Krarup-Hansen Department of Oncology, Sarcoma Unit, Herlev University Hospital, Herlev, Denmark
  • Merete Vaage-Nilsen Department of Cardiology, Herlev University Hospital, Herlev, Denmark
  • Thomas Kümler Department of Cardiology, Herlev University Hospital, Herlev, Denmark
  • Bo Zerahn Department of Clinical Physiology and Nuclear Medicine, Herlev University Hospital, Herlev, Denmark

DOI:

https://doi.org/10.1080/0284186X.2022.2082884

Keywords:

Sarcoma, cardiotoxicity, anthracycline, doxorubicin

Abstract

Background

Anthracycline induced cardiotoxicity is well recognized but only few data exist in sarcoma patients. This study retrospectively aimed to analyze sequential Cadmium Zinc Telluride (CZT)-multigated equilibrium radionuclide angiography (ERNA) for monitoring left ventricular ejection fraction (LVEF) and to assess the real-life incidence of cardiotoxicity in sarcoma patients receiving doxorubicin based chemotherapy.

Materials and methods

A retrospective analysis was performed on all sarcoma patients referred to Herlev University Hospital between 2012 and 2015. Cardiotoxicity was defined as a decline in LVEF of > 10% percentage point to a LVEF < 50% as compared to baseline. Early cardiotoxicity was defined as < 1 year and late cardiotoxicity as ≥ 1 year. Recovery of cardiotoxicity was defined as a LVEF ≥ 50%.

Results

A total of 149 patients were referred, 75 (50%) sarcoma patients were included. The main reason for exclusion was that only one CZT-ERNA had been performed in 50 (68%) of the patients. Twenty-three (31%) of the patients experienced cardiotoxicity, 11 (48%) were female, mean age was 56.9 years. Early cardiotoxicity was observed in 16 (70%) of the patients and 11 (48%) experienced clinical symptoms of cardiotoxicity at diagnosis. Recovery of LVEF was seen in 12 (55%) of the patients and persistent recovery in 10 (45%). The diastolic blood pressure at baseline was positively and significantly associated with a higher risk of developing cardiotoxicity (Relative Risk (RR): 1.039 (95% CI= 1.001 − 1.079; p = 0.042)). The median survival was 1.4 years (range 0.5 − 2.2 years) for patients with metastatic disease versus 3.9 years (range 1.5 − 6.4 years) (p = 0.009) for localized disease at baseline.

Conclusion

Cardiotoxicity is a relative frequent complication in sarcoma patients treated with doxorubicin based chemotherapy and the diastolic blood pressure at baseline was significantly associated with a higher risk of developing cardiotoxicity.

Downloads

Download data is not yet available.

Downloads

Published

2022-07-03

How to Cite

Vitfell-Rasmussen, J., Krarup-Hansen, A., Vaage-Nilsen, M., Kümler, T., & Zerahn, B. (2022). Real-life incidence of cardiotoxicity and associated risk factors in sarcoma patients receiving doxorubicin. Acta Oncologica, 61(7), 801–808. https://doi.org/10.1080/0284186X.2022.2082884